Camzyos (Mavacamten) - Patient Experience Survey |
Access to Camzyos
The Hypertrophic Cardiomyopathy Association is seeking to understand better access and barriers to care for patients with HCM who have used Camzyos, a myosin inhibitor approved for use in the USA in April 2022. This survey is voluntary and can be completed anonymously.
This survey is CONFIDENTIAL, and no personally identifiable data will be shared outside the HCMA.
This survey will give the HCMA a better understanding of how patients access Camzyos and if any pain points require attention. For example, forced "step therapy" or the use of "Co-pay accumulators" and other barriers that insurance companies may require. We also want to know if you have feedback on the REMS program.
We will be creating a report based on the findings of this survey, and we will share that report with stakeholders. These stakeholders include clinicians, healthcare providers, industry representatives, advocacy partners, patients, and families.
We remain committed to ensuring HCM patients access the therapies they and their care team have chosen. Completing this survey is strictly voluntary. You may not find a benefit to completing this survey. If you need additional information during or after completing this survey, please contact the HCMA at 973-983-7429. You may speak to Ross Hadley or Linda Montgomery.
The results of this survey will be made public in aggregate form only, meaning no individual data will be released, only statistical data.
As always, thank you for your participation in this survey!
Best Wishes,
Lisa Salberg
CEO and Founder
HCMA